<DOC>
	<DOCNO>NCT00238277</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving temozolomide radiation therapy may kill tumor cell remain surgery placement Gliadel wafer . PURPOSE : This phase II trial study well give temozolomide radiation therapy work treat patient undergone previous surgery placement Gliadel wafer newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Temozolomide During After Radiation Therapy Treating Patients Who Have Undergone Previous Surgery Placement Gliadel Wafers Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy adjuvant temozolomide administer external beam radiotherapy , term survival , patient newly diagnose glioblastoma multiforme undergone prior total surgical resection placement polifeprosan 20 carmustine implant ( Gliadel® wafer ) . OUTLINE : This open-label study . Patients undergo external beam radiotherapy 5 day week 6 week concurrently receive oral temozolomide daily 6 week . No 28 day later , patient receive additional oral temozolomide daily day 1-5 . Treatment temozolomide repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month survival . PROJECTED ACCRUAL : A total 72 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial grade IV astrocytoma ( glioblastoma multiforme ) Underwent gross total resection within past 6 week Postoperative contrastenhancing tumor extend ≤ 1 cm margin surgical cavity 68 polifeprosan 20 carmustine implant ( Gliadel® wafer ) place surgical resection cavity time surgery PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL Transaminases ≤ 4 time upper limit normal Renal Creatinine ≤ 1.7 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No know hypersensitivity reaction temozolomide No malignancy within past 5 year except curatively treat carcinoma situ basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy brain tumor No prior biologic agent ( e.g. , immunotoxins , immunoconjugates , antisense agent , peptidereceptor agonist , interferon , interleukin , tumorinfiltrating lymphocyte therapy , lymphokineactivated killer cell therapy , gene therapy ) brain tumor Chemotherapy See Disease Characteristics No prior chemotherapy brain tumor Endocrine therapy No prior hormonal therapy brain tumor Prior glucocorticoid therapy allow Radiotherapy No prior radiotherapy brain tumor Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>